Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1995 1
2008 1
2017 1
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Management of Acutely Symptomatic Hernia (MASH) study.
Proctor VK, O'Connor OM, Burns FA, Green S, Sayers AE, Hawkins DJ, Smart NJ, Lee MJ; MASH Collaborators. Proctor VK, et al. Br J Surg. 2022 Jul 15;109(8):754-762. doi: 10.1093/bjs/znac107. Br J Surg. 2022. PMID: 35608216
Are International Units of Anti-HBs Antibodies Always Indicative of Hepatitis B Virus Neutralizing Activity?
Aronthippaitoon Y, Szerman N, Ngo-Giang-Huong N, Laperche S, Ungeheuer MN, Sureau C, Khamduang W, Gaudy-Graffin C. Aronthippaitoon Y, et al. Vaccines (Basel). 2023 Apr 4;11(4):791. doi: 10.3390/vaccines11040791. Vaccines (Basel). 2023. PMID: 37112703 Free PMC article.
OBJECTIVE: Anti-HBs antibodies are elicited upon hepatitis B vaccination, and concentrations above 10 mIU/mL are considered protective. Our aim was to assess the relationship between IU/mL of anti-HBs and neutralization activity. ...
OBJECTIVE: Anti-HBs antibodies are elicited upon hepatitis B vaccination, and concentrations above 10 mIU/mL are considered protectiv …
Immunogenic effect of hepatitis B vaccine in children: comparison of two- and three-dose protocols.
Yvonnet B, Coursaget P, Petat E, Tortey E, Diouf C, Barin F, Denis F, Diop-Mar I, Chiron JP. Yvonnet B, et al. J Med Virol. 1984;14(2):137-9. doi: 10.1002/jmv.1890140207. J Med Virol. 1984. PMID: 6238131
No difference between the two groups was observed in the seroconversion rate (93.1% and 94.6%, respectively); in the proportion of high anti-HBs titer; or in the anti-HBs geometric mean titer (82 and 92 mIU/ml, respectively). These results demonstrate that two doses of 5 m …
No difference between the two groups was observed in the seroconversion rate (93.1% and 94.6%, respectively); in the proportion of high anti …
Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection.
Horsmans Y, Colle I, Van Vlierberghe H, Langlet P, Adler M, Bourgeois N, Brenard R, Michielsen P, Goossens A, Bruckers L; Belgian Assocation for the Study of the Liver. Horsmans Y, et al. Acta Gastroenterol Belg. 2008 Jul-Sep;71(3):293-7. Acta Gastroenterol Belg. 2008. PMID: 19198574 Clinical Trial.
Study aims are to evaluate the differences between standard interferon and PEG-interferon by conducting a multi-centre, controlled randomized trial comparing 3 groups. Group A : daily interferon alfa-2b at a dose of 4 MIU + ribavirin, Group B : PEG-interferon alfa-2b at a …
Study aims are to evaluate the differences between standard interferon and PEG-interferon by conducting a multi-centre, controlled randomize …
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijočević H, Karimzadeh H, Roggendorf M, Vaillant A. Bazinet M, et al. Lancet Gastroenterol Hepatol. 2017 Dec;2(12):877-889. doi: 10.1016/S2468-1253(17)30288-1. Epub 2017 Sep 28. Lancet Gastroenterol Hepatol. 2017. PMID: 28964701 Clinical Trial.
Six patients had hepatitis B surface antibody (anti-HBs) titres above 10 mIU/mL at the end of treatment (five had maximum anti-HBs concentrations of 7681-86 532 mIU/mL during treatment), which were maintained at the end of 1 year follow-up in these five patients. .. …
Six patients had hepatitis B surface antibody (anti-HBs) titres above 10 mIU/mL at the end of treatment (five had maximum anti-HBs co …
[Vaccination against hepatitis B virus. Value of intradermal administration in dialysed patients non responsive to intramuscular approach].
Poux JM, Ranger-Rogez S, Lagarde C, Benevent D, Denis F, Leroux-Robert C. Poux JM, et al. Presse Med. 1995 May 6-13;24(17):803-6. Presse Med. 1995. PMID: 7630869 French.
RESULTS: Fourteen dialysis patients (70%) developed anti-HBs > 10 mUI/ml (geometric mean titers of 330 mIU/ml). Among these, 9 developed seroprotective levels before the fifth injection. ...The geometric mean antibody level was at 3 months: 157 (n = 11), at 6 months: 12 …
RESULTS: Fourteen dialysis patients (70%) developed anti-HBs > 10 mUI/ml (geometric mean titers of 330 mIU/ml). Among these, 9 dev …